Chronic hepatitis B: what should be the goal for new therapies?
about
Hepatitis B virus and its sexually transmitted infection - an update.Current hepatitis B treatment guidelines and future research directions.Hepatitis B virus replication is blocked by a 2-hydroxyisoquinoline-1,3(2H,4H)-dione (HID) inhibitor of the viral ribonuclease H activityHepatitis B virus: new therapeutic perspectives.Viral hepatitis among drug users in methadone maintenance: associated factors, vaccination outcomes, and interventionsEngineered external guide sequences are highly effective in inhibiting gene expression and replication of hepatitis B virus in cultured cells.STING agonists induce an innate antiviral immune response against hepatitis B virus.Hydroxylated tropolones inhibit hepatitis B virus replication by blocking viral ribonuclease H activity.Covalently closed-circular hepatitis B virus DNA reduction with entecavir or lamivudine.The hepatitis B virus ribonuclease H as a drug targetHow further suppression of virus replication could improve current HBV treatment.Mutation Changes in the preC/Core Promoter in HBeAg-Positive Patients With Chronic Hepatitis B During Interferon Therapy.Hepatitis B Virus Polymerase Localizes to the Mitochondria, and Its Terminal Protein Domain Contains the Mitochondrial Targeting Signal.HBsAg and HBeAg in the prediction of a clinical response to peginterferon α-2b therapy in Chinese HBeAg-positive patientsEvolving New Strategies for the Medical Management of Chronic Hepatitis B Virus Infection.Treatment of Hepatitis B: A Concise Review.Chronic hepatitis B: A wave of new therapies on the horizon.Current treatment of hepatitis B virus infections.Metabolism and function of hepatitis B virus cccDNA: Implications for the development of cccDNA-targeting antiviral therapeutics.Therapeutic strategies for a functional cure of chronic hepatitis B virus infection.New therapies for chronic hepatitis B.Synergistic Interactions between Hepatitis B Virus RNase H Antagonists and Other Inhibitors.Establishment of an inducible HBV stable cell line that expresses cccDNA-dependent epitope-tagged HBeAg for screening of cccDNA modulators.The current status and future directions of hepatitis B antiviral drug discovery.Review article: novel therapies for hepatitis B virus cure - advances and perspectives.Toward Elimination of Hepatitis B Virus Using Novel Drugs, Approaches, and Combined ModalitiesHepatitis B virus genetic diversity has minimal impact on sensitivity of the viral ribonuclease H to inhibitors.Purification and enzymatic characterization of the hepatitis B virus ribonuclease H, a new target for antiviral inhibitors.Epigenetic Regulation of Hepatitis B Virus Covalently Closed Circular DNA: Implications for Epigenetic Therapy against Chronic Hepatitis B.Isolation and functional characterization of hepatitis B virus-specific T-cell receptors as new tools for experimental and clinical use.Hepatitis B surface antigen loss and sustained viral suppression in Asian chronic hepatitis B patients: A community-based real-world study.Discovery and Mechanistic Study of Benzamide Derivatives That Modulate Hepatitis B Virus Capsid Assembly.CRISPR/Cas9 nickase-mediated disruption of hepatitis B virus open reading frame S and X.New horizon for radical cure of chronic hepatitis B virus infection.Characterization of novel hepadnaviral RNA species accumulated in hepatoma cells treated with viral DNA polymerase inhibitorsA potent human neutralizing antibody Fc-dependently reduces established HBV infectionsHBeAg-negative chronic hepatitis patients should be monitored more strictly: a cross-sectional retrospective study on antiviral treatment-naïve patients.Advancing the regulatory path on hepatitis B virus treatment and curative research: a stakeholders consultation.Immunotherapy for Chronic Hepatitis B Virus Infection.The role of host DNA ligases in hepadnavirus covalently closed circular DNA formation.
P2860
Q30235028-4D511521-495A-44CE-A957-4F8021A08DEEQ30487002-9BDBEF9B-2592-43EE-953F-4175B5BF616CQ33911464-65278693-2131-4045-ABB2-A788CCB5763FQ34507250-0AB0C4A9-0D79-428D-BC80-AFC7055A4ECCQ34765548-4F4CC163-914A-4E35-B401-108B52CB4017Q34775644-3DB6BA51-FF87-4F0E-A561-A57A994F97C2Q35105855-9A5B6734-808C-4DBE-A662-4768378D542FQ35105877-C8CDF313-5AF9-4336-BC89-99287BA9B166Q35473087-429DBE85-89B6-4E3D-AD03-D295F7CBAF6FQ35582561-01D207E1-668D-4895-A5CF-998BD89A1682Q35622347-3ABAF088-5EEA-4259-A05F-98BE160EFC93Q36566914-AB4B6F1E-C091-44BC-A312-703C54914063Q37253020-A3D6963E-8EB5-4F7E-999A-9DE855221AD1Q37374481-BD6E43C5-4A32-426C-9441-3F900B887FC7Q37540212-E56D8C38-753D-45F2-AFCD-FFE21D933BE9Q37620340-0F3CA2EF-38C2-481C-BEEB-87B95169E1DBQ38538107-B553EDF4-06F3-4CFB-BC4E-98796B2AFDFEQ38553056-A3923CED-54D0-4B6A-BC3B-7C12977CE4C8Q38566445-57E6B57C-F837-4C91-AB40-F3003B3B7AF2Q38636988-491F99CD-4A49-44DC-B475-90AFB82D3940Q38725759-B60C9D1B-5329-413F-8995-EF26140716A1Q38726548-BC2EC67F-761A-4860-8BB7-23C46C659713Q38770516-9BA7A1E9-EB6C-4789-AF96-988EE73EA777Q38802098-65E06222-B3D5-4608-8737-C29CAD8C77F6Q38865511-656BFEFB-0524-4853-A358-0940D1A07EDCQ38980907-C6B37D93-608F-4BAD-BF0D-D4F7A7D6C559Q39332246-24D84B10-2427-42A8-986B-F3D1CAEE3AA4Q39671295-E49D582D-8397-43C7-9BA8-4D4031113B0FQ40073818-FC1A268F-FCE9-4771-B7DD-472B26CA6771Q40089302-D2F51B6C-D5AC-4887-B204-4F2A0E9F8C4BQ40172735-C680F7EB-24B3-461E-AAB4-EBA64C8B8FE9Q40178518-5E2BF332-DEBD-440C-8FAA-81552D5A9AC4Q40580426-28C54C58-1373-4459-8332-05CF0ABA35A4Q40593364-B92E305A-5D82-43A8-A8FE-0C6275D47107Q40798098-F242443E-A27F-4897-8A3D-FE3EAAB3B386Q41671765-44F13BE0-1948-4BD3-A298-48BDBD3A36CFQ41744323-CC946736-E91C-4560-879A-C98FC18D2436Q42318295-677297C2-BC65-4976-BE0F-EF13C3334F57Q47556416-3028AA80-CCE5-42B6-BF0E-C97752D5F833Q47559691-2286F903-D17D-4006-8450-7DC6A389EBD4
P2860
Chronic hepatitis B: what should be the goal for new therapies?
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Chronic hepatitis B: what should be the goal for new therapies?
@ast
Chronic hepatitis B: what should be the goal for new therapies?
@en
type
label
Chronic hepatitis B: what should be the goal for new therapies?
@ast
Chronic hepatitis B: what should be the goal for new therapies?
@en
prefLabel
Chronic hepatitis B: what should be the goal for new therapies?
@ast
Chronic hepatitis B: what should be the goal for new therapies?
@en
P2093
P2860
P1433
P1476
Chronic hepatitis B: what should be the goal for new therapies?
@en
P2093
Anand Mehta
Andrea Cuconati
Haitao Guo
Ju-Tao Guo
Robert Gish
Timothy M Block
W Thomas London
P2860
P356
10.1016/J.ANTIVIRAL.2013.01.006
P577
2013-02-04T00:00:00Z